Protagonist Therapeutics protagonist-inc.com


Public list: BIO 2016 (619) Pharma Startups (4732)

Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to 'injectable drugs'...Show all

Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening ...Show all

Company (IPO / Went public)

Phone: 510 474 0170

Fax:

7707 Gateway Boulevard
Suite 140
Milpitas, 95035
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Protagonist Therapeutics $179M Aug 7, 2018
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Protagonist Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Canaan PartnersVenture CapitalMenlo Park, California, United StatesSeries C
Lilly VenturesCorporate VentureIndianapolis, Indiana, United StatesSeries C, Series B, Series A
Adage Capital ManagementAsset/Investment ManagementBoston, Massachusetts, United StatesSeries C
Johnson & Johnson Innovation – JJDCCorporate VentureCambridge, Massachusetts, United StatesSeries C, Series B
Foresite CapitalVenture CapitalSan Francisco, California, United StatesSeries C
See all 10 investors

Competitors

Company Status Description Investors
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Hepcidin analogues and uses thereof Mar 17, 2014 Nov 21, 2017 Patent
Î�4β7 peptide monomer and dimer antagonists Oct 01, 2015 Nov 07, 2017 Patent
A4b7 integrin thioether peptide antagonists May 15, 2015 Jul 25, 2017 Patent
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul 15, 2015 Apr 18, 2017 Patent
A4b7 peptide monomer and dimer antagonists Feb 17, 2016 Dec 13, 2016 Patent
See all 19 patents